Upcoming Events

2024 Daiichi Sankyo Pharma Day®

Tuesday, July 16, 2024 (3:00 PM - 6:30 PM) (EDT)


Create New Standards of Care at Daiichi Sankyo’s 2024 Pharma Day®

MassBio’s Pharma Days are unparalleled opportunities for emerging innovators to learn from and connect with world-leading biopharmaceutical companies. 


Participate in Daiichi Sankyo’s open information session for the latest insights on its R&D strategy, target therapeutic areas, and partnering capabilities. A networking reception will follow this session. 

This is a partnering event focused on science and innovation. No solicitations.


Throughout the day on July 16, companies and researchers affiliated with a university are encouraged to apply for a one-on-one meeting with Daiichi Sankyo representatives. Daiichi Sankyo’s target therapeutic areas are*:

  • Earlier stage approaches & platforms, including:
    • Discovery platform for tumor environment-dependent functional peptides
    • Antibodies (including VHH antibodies), peptides, or small molecules with high penetration and retention in tumor stroma
    • New targets for gene therapy
  • Oncology, later stage assets
    • Post-preclinical or clinical-stage oncology programs with the potential to combine with DXd-based ADCs (or topoisomerase I inhibitors) to improve clinical outcomes by broadening the addressable population or increasing the duration of response.
    • Mechanisms of action of interest potentially include some of the following:
      • Cell Cycle regulation
      • TKI (Tyrosine Kinase Inhibitors) in priority indications
      • DDR (DNA Damage Response)
  • Non-oncology, late-stage assets (Phase 2 ongoing or later) Regional Partnerships
  • Non-oncology, research, including psychiatric disorders, cardiovascular, and others

If your company meets our eligibility guidelines, apply for a 1:1 by June 10, 2024 at 11:59 PM ET.

For more details on Daiichi Sankyo therapeutic areas, reach out to the innovation team.

Eligibility Guidelines

  • Protection of intellectual property rights (ex. patents, trademarks, copyright, trade secrets, etc.) of your concept is your responsibility and your responsibility alone.
  • Information you include in your application to MassBio will be shared with Daiichi Sankyo and other third-party pharmaceutical companies. Please note that these third-parties did NOT sign Non-Disclosure Agreements (NDAs) and therefore any information shared with them either directly or as disclosed in your application is not considered confidential information. Therefore, you should not include any information in your application that you feel could be harmful to your company should that information be disclosed or used by those receiving such information.

About Daiichi Sankyo

Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.”

In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs.

With more than 125 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 18,500 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.”

For more information, please visit


MassBioHub, Cambridge, MA
700 Technology Sq Fl 5
Cambridge, MA United States
Tuesday, July 16, 2024 (3:00 PM - 6:30 PM) (EDT)
Powered By GrowthZone